Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study

Background: Clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic heart failure and atrial fibrillation (AF) have demonstrated reduced risks of stroke and bleeding compared with vitamin K antagonists (VKAs). Here, we aim to assess the clinical efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Iksung, Oh, Jaewon, Kim, In-Cheol, Chung, Hyemoon, Lee, Jung-Hee, Kim, Hyue Mee, Byun, Young Sup, Yoo, Byung-Su, Choi, Eui-Young, Chung, Wook-Jin, Pyun, Wook Bum, Kang, Seok-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790040/
https://www.ncbi.nlm.nih.gov/pubmed/35096995
http://dx.doi.org/10.3389/fcvm.2021.765081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790040/
https://www.ncbi.nlm.nih.gov/pubmed/35096995
http://dx.doi.org/10.3389/fcvm.2021.765081

Ejemplares similares